Table of Content

Open Access iconOpen Access

ARTICLE

Chronic treatment of mice with leukemia inhibitory factor does not cause adverse cardiac remodeling but improves heart function

Carlos Zgheib1,a, Fouad Anthony Zouein1,a, Mazen Kurdi1,2, George Warren Booz1

1 Department of Pharmacology and Toxicology, School of Medicine, and the Center for Excellence in Cardiovascular-Renal Research, The Universityof Mississippi Medical Center, Jackson, Mississippi, USA
2 Department of Chemistry and Biochemistry, Faculty of Sciences, Lebanese University, Rafic Hariri Educational Campus, Hadath, Lebanon

* Corresponding Author: G.W. Booz, email

European Cytokine Network 2012, 23(4), 191-197. https://doi.org/10.1684/ecn.2012.0319

Abstract

Recent evidence suggests that the IL-6 family cytokine, leukemia inhibitory factor (LIF) is produced by cardiac cells under stress conditions including myocardial infarction and heart failure. Additionally, short-term delivery of LIF has been shown to have preconditioning effects on the heart and to limit infarct size. However, cell culture studies have suggested that LIF may exert harmful effects on cardiac myocytes, including pathological hypertrophy and contractile dysfunction. Long-term effects of LIF on the heart in vivo have not been reported and were the focus of this study. Adult male mice were injected daily with LIF (2 μg/30 g) or saline for 10 days. LIF treatment caused an approximate 11% loss in body weight. Cardiac function as assessed by echocardiography was improved in LIF-treated mice. Ejection fraction and fractional shortening were increased by 21% and 32%, respectively. No cardiac hypertrophy was seen on histology in LIF-treated mice„ there was no change in the heart-totibia length ratio, and no cardiac fibrosis was observed. STAT3 was markedly activated by LIF in the left ventricle. Different effects of LIF were seen in protein levels of genes associated with STAT3 in the left ventricle: levels of SOD2 and Bcl-xL were unchanged, but levels of total STAT3 and MCP-1 were increased. There was a trend towards increased expression of miR-17, miR-21, and miR-199 in the left ventricle of LIF-treated mice, but these changes were not statistically significant. In conclusion, effects of chronic LIF treatment on the heart, although modest, were positive for systolic function: adverse cardiac remodeling was not observed. Our findings thus lend further support to recent proposals that LIF may have therapeutic utility in preventing injury to or repairing the myocardium.

Keywords

cardiac remodeling, cytokine, cardiac dysfunction, JAK STAT signaling, cardiac repair, cardiac hypertrophy

Cite This Article

APA Style
Zgheib, C., Zouein, F.A., Kurdi, M., Booz, G.W. (2012). Chronic treatment of mice with leukemia inhibitory factor does not cause adverse cardiac remodeling but improves heart function. European Cytokine Network, 23(4), 191–197. https://doi.org/10.1684/ecn.2012.0319
Vancouver Style
Zgheib C, Zouein FA, Kurdi M, Booz GW. Chronic treatment of mice with leukemia inhibitory factor does not cause adverse cardiac remodeling but improves heart function. Eur Cytokine Network. 2012;23(4):191–197. https://doi.org/10.1684/ecn.2012.0319
IEEE Style
C. Zgheib, F.A. Zouein, M. Kurdi, and G.W. Booz, “Chronic treatment of mice with leukemia inhibitory factor does not cause adverse cardiac remodeling but improves heart function,” Eur. Cytokine Network, vol. 23, no. 4, pp. 191–197, 2012. https://doi.org/10.1684/ecn.2012.0319



cc Copyright © 2012 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 36

    View

  • 33

    Download

  • 0

    Like

Share Link